A federal magistrate judge’s July 10, 2026 scheduling order setting the first LINX reflux device lawsuit for trial on June 22, 2027 has sharpened attention on litigation that has quietly grown in Minnesota and Massachusetts federal courts. The order — issued by U.S. Magistrate Judge Elizabeth Cowan Wright in Colunga v. Torax Medical/Ethicon (D. Minnesota) — arrives just months after Johnson & Johnson completed its full withdrawal of the LINX Reflux Management System from all markets outside the United States, a process that concluded in March 2026 following J&J’s September 2025 announcement. For the thousands of patients who received LINX implants and later required device removal or revision surgery, the convergence of these events makes this the most consequential moment yet in LINX reflux device lawsuit history.
What Is the LINX Device and Why Are Patients Suing?
The LINX Reflux Management System is a small ring of titanium-encased magnetic beads surgically implanted around the lower esophageal sphincter (LES) to treat chronic gastroesophageal reflux disease (GERD). The device was designed by Torax Medical and received FDA premarket approval (PMA) in 2012 under application number P100049. Johnson & Johnson’s Ethicon subsidiary acquired Torax in 2017, inheriting both the product and its growing safety record. According to peer-reviewed literature, more than 40,000 LINX devices have been implanted globally since 2012.
The central allegation in every active LINX reflux device lawsuit traces back to a manufacturing defect: titanium beads can separate from their wire links, creating what the FDA described as a “discontinuous or open” device. Once the ring loses structural integrity, it can migrate within the body, puncture surrounding organs, erode into the esophagus, or cause dense scar tissue adhesions to the liver, colon, or lungs. The American Gastroenterological Association has specifically flagged LINX erosion as “a significant risk,” adding clinical weight to patient claims. Plaintiffs who underwent painful revision surgery or full explantation — sometimes years after implantation — now argue that Torax and Ethicon knew about the defect and failed to address it adequately before placing devices in tens of thousands of patients.
The 2018 Recall: Manufacturing Defect at the Core of Every Viable Claim
In May 2018, Torax Medical issued a Class II recall covering 9,131 LINX devices after confirming that a manufacturing defect allowed the titanium beads to separate from their wire links. The recall was classified Class II — meaning the FDA determined the defect could cause temporary or medically reversible adverse health consequences, though not ruling out more serious outcomes. By the time the recall was announced, at least 526 adverse events had already been reported to the FDA’s Manufacturer and User Facility Device Experience (MAUDE) database, many specifically involving bead separation and device migration — the exact failure mode the recall addressed.
The recall is more than a safety milestone; it is the legal linchpin of every surviving LINX reflux device lawsuit. Because LINX is a PMA-approved device, the U.S. Supreme Court’s decision in Riegel v. Medtronic (2008) imposes federal preemption on design-defect and failure-to-warn claims, effectively shielding manufacturers from those theories. Only claims alleging that a specific device deviated from FDA-approved manufacturing specifications — a manufacturing defect — survive preemption. The 2018 recall, which documented exactly that kind of deviation, gives plaintiffs the evidentiary hook needed to plead a viable parallel claim under state law without triggering preemption dismissal. Attorneys evaluating cases focus intensely on whether a plaintiff’s implanted device falls within the recalled lot numbers. If you believe you may qualify, using a medical malpractice calculator to estimate potential compensation is a useful first step before consulting counsel.
Key LINX Litigation Statistics at a Glance
| Data Point | Figure | Source |
|---|---|---|
| Global LINX implants since 2012 | 40,000+ | Peer-reviewed literature / FDA |
| Devices covered by 2018 Class II recall | 9,131 | FDA recall records |
| Adverse events in MAUDE database at recall | 526+ | FDA MAUDE database |
| Estimated 5-year explantation rate | Up to 7% | Peer-reviewed clinical studies |
| OUS market withdrawal completion date | March 2026 | J&J / MassDevice |
| First trial date (Colunga v. Torax/Ethicon) | June 22, 2027 | D. Minnesota scheduling order, July 10, 2026 |
| Second trial date (Wingett v. Torax/Ethicon) | May 2028 | D. Minnesota, June 2026 ruling |
| Third trial date (Lopez v. Torax/Ethicon) | March 2028 | D. Minnesota, filed January 2026 |
J&J’s Global Market Withdrawal: What It Means for Litigation
In September 2025, Johnson & Johnson announced it would withdraw the LINX device from all markets outside the United States (OUS), with the withdrawal to be completed by March 2026. The company cited “commercial reasons” rather than safety or efficacy concerns — a characterization that plaintiff attorneys are expected to scrutinize closely as discovery proceeds. The OUS withdrawal is now fully complete as of the writing of this article, meaning patients in Europe, Australia, and other international markets can no longer receive new implants, though existing devices remain in place.
Critically, LINX has not been withdrawn from the U.S. market. In fact, the device recently received expanded FDA labeling in the United States, and it remains available domestically. This creates a legally nuanced landscape: international patients injured by LINX face different regulatory and jurisdictional challenges, while U.S. plaintiffs must navigate federal preemption doctrine even as the device stays on the American market. The selective withdrawal may nonetheless prove relevant at trial as evidence of the company’s internal risk assessments. For those tracking mass tort litigation trends, the federal court dockets for the District of Minnesota and District of Massachusetts carry the most current filings in this litigation.
Trial Calendar: Three Cases Now Scheduled in Federal Court
The LINX reflux device lawsuit landscape moved decisively forward in the summer of 2026 with the establishment of a three-case trial calendar. On July 10, 2026, U.S. Magistrate Judge Elizabeth Cowan Wright issued a scheduling order in Colunga v. Torax Medical and Ethicon (D. Minnesota), setting the case for a jury trial beginning June 22, 2027. This would be the first LINX case ever presented to a federal jury, and its outcome is expected to heavily influence settlement negotiations across all pending cases.
A second case, Wingett v. Torax Medical and Ethicon (D. Minnesota, filed February 2026), was cleared for trial in May 2028 pursuant to a June 2026 ruling. A third case, Lopez v. Torax Medical and Ethicon (D. Minnesota, filed January 2026), was separately scheduled for March 2028. Together, these three trial dates create a rolling bellwether structure — even absent a formal multidistrict litigation (MDL) designation — that will generate jury verdicts, evidentiary rulings, and damages data invaluable to every plaintiff currently in litigation. No MDL has been formed as of mid-2026, but if individual filings continue to accumulate at the current pace across D. Minnesota and D. Massachusetts, an MDL petition becomes increasingly likely in the second half of 2026 or 2027. Individuals evaluating their own potential claims can get a preliminary sense of damages ranges using a personal injury settlement calculator while awaiting legal consultation.
Who Qualifies to File a LINX Reflux Device Lawsuit?
Eligibility for a LINX reflux device lawsuit is defined by the intersection of medical history, device lot number, and timing. The strongest candidates are patients who received a LINX implant and subsequently experienced one or more of the following: bead separation confirmed on imaging, device migration within the body, esophageal erosion or perforation, scar tissue adhesions to the liver, colon, or lungs, organ damage requiring intervention, or the need for revision surgery or full explantation. Patients who experienced complications but never required surgical intervention face a higher evidentiary burden and should still consult with an attorney, as documented adverse events reported to their physician may support a claim.
The manufacturing defect track — the only theory likely to survive federal preemption — requires demonstrating that a plaintiff’s specific device deviated from Torax’s FDA-approved manufacturing specifications in the manner identified by the 2018 Class II recall. Retaining implant records, surgical reports, device lot numbers, and any FDA adverse event correspondence is essential. State statutes of limitations for medical device injury claims typically run one to four years from the date of injury discovery, not implantation — meaning patients who only recently discovered their complications through follow-up imaging may still be within the filing window. Federal and state statutes of limitations vary, and an attorney review is necessary to confirm your specific deadline.
Frequently Asked Questions About the LINX Reflux Device Lawsuit
What injuries are most commonly linked to the LINX device in current lawsuits?
The most commonly alleged injuries in active LINX reflux device lawsuit filings include bead separation from the wire link assembly, device migration within the abdominal cavity, esophageal erosion or perforation, formation of scar tissue adhesions to adjacent organs such as the liver, colon, or lung, and organ damage requiring corrective surgery. Patients who underwent explantation — device removal — are among the most frequently represented plaintiffs. Clinical data shows that up to 7% of LINX recipients require explantation within five years of implantation, which translates to potentially thousands of patients across the 40,000-plus global implant population who may have viable claims.
Why can’t LINX plaintiffs sue for design defects or failure to warn?
The LINX device received FDA approval through the Premarket Approval (PMA) process under application P100049 in 2012. Under the U.S. Supreme Court’s ruling in Riegel v. Medtronic (2008), state-law claims that impose requirements different from or in addition to FDA requirements are preempted by federal law. This means design-defect claims — arguing the device was inherently unsafe — and failure-to-warn claims — arguing patients were not adequately informed of risks — are generally dismissed on preemption grounds. The only surviving theory is a parallel manufacturing defect claim, which argues the manufacturer deviated from its own FDA-approved specifications. The 2018 Class II recall, which documented exactly that deviation in 9,131 devices, is the factual foundation that makes these parallel claims viable.
Is there an MDL for LINX lawsuits, and what courts are handling these cases?
As of mid-2026, no Multidistrict Litigation (MDL) has been established for LINX reflux device lawsuits. Individual cases are being filed and litigated primarily in the U.S. District Court for the District of Minnesota — where Torax Medical is headquartered and where the three scheduled trial cases are pending — and in the U.S. District Court for the District of Massachusetts. Legal observers note that if filing volume continues to increase through the second half of 2026 and into 2027, a plaintiff’s steering committee or individual firm may petition the Judicial Panel on Multidistrict Litigation (JPML) to consolidate cases for coordinated pretrial proceedings. The June 22, 2027 trial date in Colunga is being watched as a potential catalyst for either settlement discussions or expanded MDL activity.
What does J&J’s withdrawal of LINX from international markets mean for my case?
Johnson & Johnson announced in September 2025 that it would withdraw LINX from all markets outside the United States by March 2026, a deadline that has now passed. J&J stated the withdrawal was for “commercial reasons” unrelated to safety or efficacy. For U.S. plaintiffs, this withdrawal does not directly affect their legal claims, since the device remains available domestically and recently received expanded FDA labeling in the United States. However, plaintiff attorneys are expected to use the OUS withdrawal as discovery leverage, seeking internal communications, risk analyses, and commercial performance data that led to the decision. Such documents could potentially illuminate what J&J and Ethicon knew about adverse event rates and device performance in markets where post-market surveillance requirements may differ from those in the U.S.
What is the statute of limitations for filing a LINX device lawsuit in 2026?
Statutes of limitations for medical device injury claims vary by state, but most jurisdictions allow one to four years from the date of injury discovery — not the original implant date. This distinction is critical for LINX patients: if you received your implant in 2014 or 2016 but only recently discovered through follow-up imaging or a physician consultation that your device had experienced bead separation or migration, your filing clock may have started relatively recently rather than at implantation. Some states also recognize a “discovery rule” tolling provision that pauses the limitations period while the defect was inherently undiscoverable. Given the complexity of PMA preemption analysis and state-specific limitations rules, anyone who received a LINX device and experienced subsequent complications should seek legal evaluation promptly to preserve their rights — statutes of limitations are strictly enforced and cannot be extended once they expire.
Legal Disclaimer: The information provided on this page is for general informational purposes only and does not constitute legal advice, create an attorney-client relationship, or substitute for consultation with a licensed attorney in your jurisdiction.
Related reading: General Surgery Malpractice Settlement Amounts: 2026 Data, Verdicts & How Compensation Is Calculated
Related reading: Robotic Surgery Malpractice Settlement Amounts: 2026 Data, Verdicts & How Compensation Is Calculated
Victoria Chambers is a mass tort and class action research analyst with extensive knowledge of multi-district litigation (MDL), defective product cases, dangerous drug lawsuits, and toxic exposure claims across the United States. Victoria is not an attorney and the information provided is for educational purposes only.